NovaBay Pharmaceuticals, Inc. (NBY) |
0.077 0.005 (6.21%) 04-23 16:00 |
Open: | 0.0703 |
High: | 0.0781 |
Low: | 0.068 |
Volume: | 1,564,470 |
Market Cap: | 3(M) |
PE Ratio: | -0.02 |
Exchange: | American Stock Exchange |
Industry: | Biotechnology |
Sector: | Healthcare |
Technical analysis | ||||
sell | buy |
Resistance 2: | 0.15 |
Resistance 1: | 0.12 |
Pivot price: | 0.09 |
Support 1: | 0.06 |
Support 2: | 0.05 |
52w High: | 1.42 |
52w Low: | 0.068 |
NovaBay Pharmaceuticals, Inc., a pharmaceutical company, develops and sells eyecare and skincare products in the United States and internationally. It offers Avenova, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products under the NeutroPhase and PhaseOne brands. The company also provides dermatological solutions to address skincare concerns comprising keratosis pilaris, rosacea and eczema, anti-aging, SPF, hyperhidrosis, excessive hair, and acne under the DERMAdoctor brand. It sells its products through retailers, digital beauty channels, and distributors, as well as online. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.
EPS | -7.050 |
Book Value | 0.770 |
PEG Ratio | 0.00 |
Gross Profit | 0.000 |
Profit Margin (%) | -93.83 |
Operating Margin (%) | -34.18 |
Return on Assets (ttm) | -24.5 |
Return on Equity (ttm) | -132.0 |
Fri, 19 Apr 2024
NovaBay Pharmaceuticals Receives a NYSE American Notice Regarding Stockholder Equity - Business Wire
Thu, 28 Mar 2024
NovaBay Pharmaceuticals Reports 2023 Fourth Quarter and Full Year Financial Results - Vision Monday
Wed, 27 Mar 2024
Novabay Pharmaceuticals Down 22.01% To $0.11 After Earnings Beat - InvestorsObserver
Tue, 26 Mar 2024
NBY Stock Earnings: NovaBay Pharmaceuticals Beats EPS, Beats Revenue for Q4 2023 - InvestorPlace
Tue, 26 Mar 2024
NovaBay Pharmaceuticals, Inc. (NBY) Q4 2023 Earnings Call Transcript - Seeking Alpha
Thu, 14 Mar 2024
NovaBay sells skincare unit to focus on eyecare growth - Investing.com
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |